AstraZeneca PLC
AZN · NASDAQ
9/30/2025 | 6/30/2025 | 3/30/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 7.48 | -1.39 | 0.21 | 6.23 |
| FCF Yield | 1.85% | 0.68% | 1.44% | 0.96% |
| EV / EBITDA | 51.43 | 48.92 | 50.51 | 81.07 |
| Quality | ||||
| ROIC | 3.22% | 3.20% | 3.90% | 2.33% |
| Gross Margin | 81.16% | 82.89% | 83.51% | 81.70% |
| Cash Conversion Ratio | 2.03 | 1.08 | 1.27 | 1.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.91% | 8.30% | 7.84% | 6.83% |
| Free Cash Flow Growth | 204.03% | -55.45% | 68.24% | -3.60% |
| Safety | ||||
| Net Debt / EBITDA | 4.77 | 5.20 | 5.26 | 8.77 |
| Interest Coverage | 10.27 | 7.99 | 10.53 | 4.75 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.38 | 0.38 | 0.52 |
| Cash Conversion Cycle | -494.77 | -549.37 | -581.32 | -488.91 |